Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP552021.RASS4T6VhFS2Dlg82HDpuYQQXzaDOWvcN0tHi_Lg8Q_SE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP552021.RASS4T6VhFS2Dlg82HDpuYQQXzaDOWvcN0tHi_Lg8Q_SE130_assertion type Assertion NP552021.RASS4T6VhFS2Dlg82HDpuYQQXzaDOWvcN0tHi_Lg8Q_SE130_head.
- NP552021.RASS4T6VhFS2Dlg82HDpuYQQXzaDOWvcN0tHi_Lg8Q_SE130_assertion wasGeneratedBy ECO_0000203 NP552021.RASS4T6VhFS2Dlg82HDpuYQQXzaDOWvcN0tHi_Lg8Q_SE130_provenance.
- NP552021.RASS4T6VhFS2Dlg82HDpuYQQXzaDOWvcN0tHi_Lg8Q_SE130_assertion wasDerivedFrom befree-2016 NP552021.RASS4T6VhFS2Dlg82HDpuYQQXzaDOWvcN0tHi_Lg8Q_SE130_provenance.
- NP552021.RASS4T6VhFS2Dlg82HDpuYQQXzaDOWvcN0tHi_Lg8Q_SE130_assertion SIO_000772 16733374 NP552021.RASS4T6VhFS2Dlg82HDpuYQQXzaDOWvcN0tHi_Lg8Q_SE130_provenance.
- NP552021.RASS4T6VhFS2Dlg82HDpuYQQXzaDOWvcN0tHi_Lg8Q_SE130_assertion evidence source_evidence_literature NP552021.RASS4T6VhFS2Dlg82HDpuYQQXzaDOWvcN0tHi_Lg8Q_SE130_provenance.
- NP552021.RASS4T6VhFS2Dlg82HDpuYQQXzaDOWvcN0tHi_Lg8Q_SE130_assertion description "[To evaluate in naive patients with chronic hepatitis C 1- the efficacy and safety of one month interferon alpha (IFN-alpha) induction regimen; 2- the potential virological benefit of a secondary adjunction of ribavirin among HCV RNA negative patients after 20 weeks of IFN therapy, with or without an initial 4-week IFN induction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP552021.RASS4T6VhFS2Dlg82HDpuYQQXzaDOWvcN0tHi_Lg8Q_SE130_provenance.